Aura’s CEO Describes the Challenges of Ocular Melanoma

Elisabet “Eli” de los Pinos founded Aura Biosciences in 2009 to chase down innovative treatments for cancer. AURA, which made its first presentation at OIS in 2015, is reporting promising progress with AU-O11, a drug delivery technology that can deliver cancer-killing drugs to the surface of the eye. Speaking With: Elisabet de los Pinos, PhD…

Read More

Aura Biosciences Offers Hope for Ocular Melanoma

OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 067″] Elisabet “Eli” de los Pinos was enjoying her job at Eli Lilly’s Oncology Business Unit where she was part of the leadership team responsible for Alimta’s market launch in Europe, a new drug for the treatment of Lung Cancer. But she took the leap, leaving corporate comfort to build Aura…

Read More

Aura Biosciences

Patients with ocular melanoma have very few treatment options, and those that exist – removal of the eye or plaque radiation – leave them blind within two years. Aura Biosciences has received orphan drug designation from the Food and Drug Administration for its class of intravitreal therapies that target ocular melanoma, founder and CEO Elisabet…

Read More

Iconic Therapeutics

Participant: William L. Greene, MD Dr. Greene has served as CEO of Iconic Therapeutics since 2014. He brings 20 years of experience as an operating executive, clinician, investor, and entrepreneur. View Full Profile

Read More

RXi Shortens Strands for Effective Drug Delivery

Geert Cauwenbergh, President & CEO for RXi Pharmaceuticals, shares the company’s role in making RNAI relevant to ophthalmology. Highlighting their research surrounding the delivery of drug to the eye, Geert expands on their unique modification to create shorter passenger strands to accompany the longer guide strand to facilitate delivery to the eye effectively. Presenter: Geert…

Read More